High-Cell-Density Culture to Produce Plasmid DNA for Gene Therapy in E. coli - How to produce Plasmid DNA in a high-cell-density culture. - BioPharm International

ADVERTISEMENT

High-Cell-Density Culture to Produce Plasmid DNA for Gene Therapy in E. coli

REFERENCES

1. Prazeres D, Ferreira G, Monteiro G, Cooney C, Cabral J. Large-scale production of pharmaceutical-grade plasmid DNA for gene therapy. Trends Biotechnol. 1999;17(4):169–74.

2. Prather KJ, Sagar S, Murphy J, Chartrain M. Industrial scale production of plasmid DNA for vaccine and gene therapy: Plasmid design, production and purification. Enzyme Microb Technol. 2003;33:865–83.

3. Schleef M, editor. Biotechnology. Volume 5a: Recombinant Proteins, Monoclonal antibodies and Therapeutic Genes. Hoboken, NJ: Wiley & Sons; 1999. p. 445–69.

4. Vogel FR, Sarver H. Nucleic acid vaccines. Clin Microbiol. 1995;8:406–10.

5. Robinson HL. DNA vaccines. Clin Microbiol Newslett. 2000;23:17–22.

6. Herweijer H, Wolf J. Progress and prospects: Naked DNA gene transfer and therapy. Gene therapy. 2003;10:453–8.

7. Chattergoon M, Boyer J, Weiner DB. Gene immunization: A new era in vaccines and immune therapeutics. FASEB. 1997 Aug;11(10):753–63.

8. O'Kennedy R, Ward J, Keshavarz E. Effects of fermentation strategy on the characteristics of plasmid DNA production. Biotecnol Appl Biochem. 2003 Feb;37 (Pt 1):83–90.

9. Kim B, Shuler M. Analysis of pBR322 replication kinetic and its dependency on growth rate. Biotechnol Bioeng. 1990;36:233–42.

10. Xu Z, LiuG, Cen P, Wong W. Factors influencing secretive production of human epidermal growth factor (hEGF) with recombinant E. coli K12. Bioprocess Biosyst Eng. 2000;23:669–74.

11. Miller G. Anal. Chem. 1959 31:426–8.

12. Birnboim HC, Doly J. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res. 1979;7:1513–23.

13. Shiloach J, Fass R. Growing E. coli to high cell density—A historical perspective on method development. Biotechnol Adv. 2005;23:345–57.

14. Carnes A. Fermentation design for the manufacture of therapeutic plasmid DNA. BioProcess Int. 2005 Oct;3(9):36–44.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
Author Guidelines
Source: BioPharm International,
Click here